Hong Kong · Delayed Price · Currency is HKD Hua Medicine (Shanghai) Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 93% year-over-year to nearly RMB 500 million, driven by a 91% increase in sales volume and expanded market access. Gross profit margin improved, selling expenses dropped, and profitability was achieved in commercialization. Patent and NRDL price extensions support long-term growth.
-
Revenue more than doubled year-over-year in H1 2025, driven by Dorzagliatin's commercialization and operational efficiency, with gross margin rising to 54%. Confident in reaching RMB 1 billion sales by 2027, supported by global expansion and new product launches.
Fiscal Year 2024
-
Transitioned to full commercialization, ending Bayer partnership and driving dorzagliatin sales growth. Net sales surged nearly 200% early in 2025, with a strong cash position and plans to reach RMB 1 billion sales and break-even by 2027. Expanding into new markets and developing a second-generation GKA.